Quoin announces clinical data from ongoing Pediatric Netherton Syndrome study

Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The Investigator Pediatric Study continues to demonstrate significant improvement in the skin area treated with QRX003 versus the non-treated area. At the mid-point of the testing period the Investigator’s Global Assessment of the skin condition improved from “Severe” at baseline to “Mild” after six weeks of dosing twice a day with QRX003, indicating a very substantial improvement in a short period of testing. As a result of these results, the subject is being transitioned to having QRX003 applied to their whole body surface area as opposed to the approximately 20% of their BSA that was being tested for the initial 6 weeks. In addition, there have been no adverse events or safety concerns reported to date for this subject, which is consistent with observations from each of Quoin’s ongoing clinical studies in Netherton Syndrome subjects.